WeTrials
Recruiting

A Pilot Study of APG-157 With Bevacizumab for Patients With Recurrent High-Grade Glioma

What is this study?

This study is testing a new medication called APG-157 combined with a standard medicine called Bevacizumab to see how well they work together against a fast-growing brain tumor called high-grade glioma. Doctors want to see if this combination helps patients live longer, improves their quality of life, and helps shrink the tumor.

Who can participate?

You might be able to join if you are 19 or older, have a lab-confirmed diagnosis of an advanced brain tumor that has grown despite previous treatments, and have recovered from the side effects of past therapies. Women who are pregnant or breastfeeding, or anyone with severe organ problems or allergies to the study medications, cannot take part.

What will happen?

Participants will take the study drug, APG-157, by dissolving six pastilles in their mouth every day—two at breakfast, two at lunch, and two at dinner. You will also continue to receive Bevacizumab as part of your standard medical care.

Where and when?

The study is currently active and recruiting patients in Rochester, Minnesota, and Omaha, Nebraska, in the United States.

Key Points
  • 1Tests a new medication (APG-157) alongside a standard brain tumor treatment.
  • 2Involves dissolving six pastilles in your mouth daily while continuing standard care.
  • 3Currently recruiting patients in Minnesota and Nebraska.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
GliomaGlioblastoma Multiforme

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.